

Complement mutations in *DGKE*-associated atypical hemolytic uremic syndrome.

Running title: Complement mutations in *DGKE*-associated aHUS.

Subject of manuscript: Inherited and genetics diseases

Daniel Sánchez Chinchilla^{1,2,#}, Sheila Pinto^{1,2,#}, Bernd Hoppe³, Marta Adragna⁴, Laura Lopez⁴, Maria Luisa Justa Roldan⁵, Antonia Peña⁶, Margarita Lopez Trascasa^{2, 7}, Pilar Sánchez-Corral^{2, 8} and Santiago Rodríguez de Córdoba^{1,2,*}.

#) Equal contribution authors

1) *Centro de Investigaciones Biológicas, Consejo Superior de Investigaciones Científicas, Madrid, Spain.*

2) *Centro de Investigación Biomédica en Enfermedades Raras, Madrid, Spain.*

3) *Department of Pediatrics, Division of Pediatric Nephrology. University of Bonn, Bonn, Germany.*

4) *Department of Nephrology, Hospital de Pediatría Prof. Dr. Juan P. Garrahan, Buenos Aires, Argentina*

5) *Servicio de Nefrología Pediátrica, Hospital Universitario Infantil Miguel Servet. Zaragoza, Spain*

6) *Servicio de Nefrología Pediátrica, Hospital Universitario La Paz/IdiPAZ, Madrid, Spain*

7) *Unidad de Inmunología, Hospital Universitario La Paz/IdiPAZ, Madrid, Spain.*

8) *Unidad de Investigación, Hospital Universitario La Paz/IdiPAZ, Madrid, Spain.*

*) Corresponding author: Prof. Santiago Rodríguez de Córdoba

Centro de Investigaciones Biológicas

Ramiro de Maeztu 9, Madrid 28040, Spain.

Tel: (+34) 91 7373112 x4432

E-mail: srdecordoba@cib.csic.es

Word count

Abstract: 280

Text: 3177

ABSTRACT

Background and objectives.

Atypical hemolytic uremic syndrome (aHUS) is characterized by vascular endothelial damage usually due to complement dysregulation. Consistently, complement inhibition therapies are highly effective in most aHUS patients. Recently, it was shown that a significant percentage of early-onset aHUS cases carry mutations in diacylglycerol kinase- ϵ (*DGKE*), an intracellular protein with no obvious role in complement. These data support an alternative, complement-independent, mechanism leading to thrombotic microangiopathy that has implications for treatment of early-onset aHUS. To get further insights into this new form of aHUS we analyzed the *DGKE* gene in our aHUS cohort.

Design, setting, participants and measurements.

Eighty-three patients with early-onset aHUS (<2y), enrolled in the Spanish aHUS registry between 1999 and 2013, were screened for mutations in *DGKE*. These patients were also fully characterized for mutations in *CFH*, *MCP*, *CFI*, *C3*, *CFB* and *THBD*, *CFH*-*CFHRs* copy number variations and rearrangements, and anti-factor H antibodies.

Results.

We found four patients carrying mutations in *DGKE*, one p.H536Qfs*16 homozygote and three compound heterozygotes (p.W322*/p.P498R, two patients; p.Q248H p.G484Gfs*10, one patient), who also carry heterozygous mutations in *THBD* or *C3*. Extensive plasma infusions controlled aHUS recurrences and prevented renal failure in the two patients with *DGKE* and *THBD* mutations. A positive response to plasma infusions and complement inhibition treatment was also observed in the patient with concurrent *DGKE* and *C3* mutations.

Conclusions.

Our data suggest that complement dysregulation influence the onset and disease severity in carriers of *DGKE* mutations, and that treatments based on plasma infusions and complement inhibition are potentially useful in those patients with combined *DGKE*

and complement mutations. A comprehensive understanding of the genetic component predisposing to aHUS is therefore critical to guide an effective treatment.

Keywords: Complement, *DGKE*, aHUS, thrombotic microangiopathy.

INTRODUCTION

Hemolytic uremic syndrome (HUS) is a rare, life threatening disease characterized by thrombocytopenia, haemolytic anemia and acute renal failure¹. The most frequent form of HUS follows a diarrheal prodrome and is associated with infections involving shiga-toxin (Stx)-producing *E. coli* strains. Five to ten percent of HUS patients lack an association with this type of infections. This atypical form of HUS (aHUS) has the poorest long-term prognosis; it is characterized by recurrences and presents a mortality rate approaching 30%^{1, 2}. Genetic analysis in aHUS patients have revealed that most cases associate with mutations and polymorphisms in complement genes and that the disease develops as a consequence of defective protection of cellular surfaces from complement activation³⁻¹⁷. The recognition that aHUS is a disorder involving complement-dependent tissue damage provided strong support for the implementation of aHUS therapies based in complement inhibitors¹⁸.

In contrast to this complement-related aHUS, Lemaire et al. (2013)¹⁹ have reported that as many as 27% of aHUS cases presenting in the first year of life are caused by the deficiency of diacylglycerol kinase- ϵ (DGK- ϵ) encoded by the *DGKE* gene. It has been proposed that lack of DGK- ϵ causes enhanced signaling through arachidonic acid-containing DAGs and results in a pro-thrombotic phenotype^{19, 20}. Because these patients lacked discernable complement alterations it was suggested that *DGKE*-associated aHUS represents an alternative mechanism leading to thrombotic microangiopathy that is independent of complement dysregulation¹⁹.

To get further insights into this new form of aHUS and to estimate the prevalence of carriers of *DGKE* mutations in the aHUS Spanish cohort we performed the analysis of the *DGKE* gene in 83 cases with a disease onset in the first two years of life.

PATIENTS, MATERIALS and METHODS.

Patients.

Our aHUS cohort includes patients, mainly of Spanish origin, enrolled since 1999. We have performed complement studies that have allowed us to identify mutations, risk haplotypes and auto antibodies in these patients, most of which have already been published. Currently, our cohort includes 289 aHUS patients, 262 from Spain, 9 from other European countries, 4 from the North of Africa (Morocco, Tunisia, Senegal), 6 from USA, and 8 from South America. All these cases were diagnosed at specific centers in the countries mentioned and subsequently submitted to the Spanish aHUS registry for complement functional and genetic analysis. aHUS was diagnosed based on microangiopathic hemolytic anemia and thrombocytopenia defined by an hematocrit (Ht) less than 0.3 (30%), hemoglobin (Hb) level less than 10g/dL, serum lactate dehydrogenase (LDH) level greater than 460U/L, undetectable haptoglobin level, fragmented erythrocytes in the peripheral blood smear, and platelet count less than 150,000/ μ L, associated with acute renal failure. The studies reported here have Institutional Review Board's approval. Informed consent was provided to all individuals participating in the study, according to the Declaration of Helsinki.

Complement profile assessment.

Serum concentrations of C3 and C4 were evaluated by nephelometry (Siemens. Marburg. Germany). Factor H (FH) and factor I (FI) serum levels were measured by ELISA^{21, 22}. Membrane cofactor protein (MCP; CD46) levels on peripheral blood cells were determined by flow cytometry⁸. The presence of anti FH antibodies and C3 nephritic factor, and the functional analysis of FH using the sheep erythrocytes hemolysis assay were performed as previously described²³⁻²⁵.

Mutation screening and genotyping.

Exons of the *CFH*, *MCP*, *CFI*, *C3*, *CFB* and *THBD* genes were amplified from

genomic DNA using primers derived from the intronic sequences as described^{5, 10, 11, 13, 26}. Exons of *DGKE* were amplified with the primers described in Supplementary Table 1. Automatic sequencing was performed in an ABI3730 sequencer using a dye terminator cycle sequencing kit (Applied Biosystems). Copy number variations and genomic rearrangements were assessed by multiplex ligation-dependent probe amplification (MLPA) and custom-designed high-density 8x15k oligonucleotide CGH arrays spanning the *RCA* gene cluster (median resolution: 110bp) (AMADID 040193, Agilent Technologies, Santa Clara, CA)²⁷. *CFH* and *MCP* genotyping was performed as described previously⁸.

***In silico* analysis of mutations.**

The probability of a genetic variant to result in structural or functional alterations was calculated using bioinformatics prediction tools that discriminate neutral polymorphisms from amino acid substitutions of likely functional importance. To minimize the possibility of false positive or negative results we have applied four different computational algorithms publicly available, namely, Sorting Intolerant From Tolerant²⁸ (SIFT, <http://sift.jcvi.org>), Polymorphism Phenotyping²⁹ (PolyPhen, <http://genetics.bwh.harvard.edu>), Mutation Taster³⁰ (<http://www.mutationtaster.org>) and Align-GVGD³¹ (<http://agvgd.iarc.fr>). The SIFT algorithm predicts whether an amino acid substitution affects protein function based on sequence homology among related genes and domains over evolutionary time, and the physico-chemical properties of the amino acid residues. Polyphen also incorporates the analyses of sequence conservation and the nature of the amino acid residues involved, as well as the location of the substitution within the structure of the protein. By accessing a variety of heterogeneous biological databases and analytical tools, MutationTaster is able to identify the missense mutations most likely to have functional effects, such as changes to the transcriptional level and pre-mRNA splicing. Align-GVGD combines the biophysical characteristics of amino acid

and protein multiple sequence alignments to predict where missense substitutions in genes of interest fall in a spectrum from enriched deleterious to enriched neutral.

RESULTS

The Spanish aHUS cohort includes 83 patients, enrolled between 1999 and 2013, with a disease onset in the first two years of life; sixty-two of them without a discernable genetic or autoimmune abnormality that helps to explain the development of the disease. We performed the analysis of the *DGKE* gene and found that one of these patients (HUS299) was homozygote for a frameshift *DGKE* mutation. We also screened the 21 early-onset aHUS patients with identified genetic factors and, surprisingly, found three additional patients, belonging to two unrelated pedigrees, carrying compound heterozygous mutations in *DGKE* (Figure 1, Figure 2 and Table 1). We did not find heterozygote carriers of *DGKE* mutations in our aHUS cohort.

Patients with isolated DGKE mutations.

HUS299 is a 4y-old male from Marroco who presented with aHUS at 13m-old, coincident with a diarrhea episode. He required peritoneal dialysis during 22 days, but evolved well, without recurrences. Three years after remission, the patient remains asymptomatic with only a residual microalbuminuria (Table 2; Supplementary Data). HUS299 is homozygous for a frameshift mutation in exon 12 (c.1608_1609del; p.H536Qfs*16) of *DGKE* that results in a truncated DGK- ϵ protein lacking the last 31 amino acids (Figures 1 and 2 and Table 1), which is very likely deleterious. This is a novel *DGKE* genetic variation that has not been found in 80 control chromosomes from North African populations and it is not described in the available databases. Additional genetic analysis in this patient failed to reveal other genetic abnormalities. He was also negative for anti FH autoantibodies and his plasma complement protein levels, including C3 were normal (Table 3).

Patients with concurrent mutations in DGKE and THBD.

HUS40 and HUS39 are siblings from an Argentinean family of European ancestry. HUS40 presented with HUS at 7mo of age. Five months later she had a recurrence that

required hemodialysis and continuous ambulatory peritoneal dialysis for few months. She evolved satisfactorily, partially recovering renal function without dialysis requirement. A third recurrence occurred at 2y old that responded well to a protocol of daily plasma infusions, which were suspended one year later. She had not suffered any more recurrences. She is now 17y-old and is clinically well, with normal blood parameters, serum creatinine of 1.5mg/dl and Ccr of 41ml/min/1.73m² (Table 2; Supplementary Data). Her brother, HUS39, presented with aHUS at 3mo-old. He was anuric, requiring acute peritoneal dialysis. Based on the experience with his sister (HUS40), he was immediately treated with daily plasma infusions. After 10 days, his renal function improved and he was discharged maintaining the daily plasma infusions for two months (10ml/kg/day). Interestingly, when plasma infusions were spaced biweekly he had an aHUS recurrence that responded well when plasma infusions were returned to daily basis. Based on his clinical improvement, plasma infusions were again spaced progressively and finally suspended five years later. He is now 11y-old and is clinically well, with normal blood parameters, serum creatinine of 0.8mg/dl and Ccr of 57ml/min/1.73m² (Table 2; Supplementary Data).

HUS40 and HUS39 are compound heterozygotes for a non-sense mutation (c.966G>A; p.W322*) in exon 6 and a missense mutation (c.1493C>G; p.P498R) in exon 11 of the *DGKE* gene (Figures 1 and 2 and Table 1). The p.W322* mutation has been described previously as a pathogenic mutation associated with a rare European haplotype¹⁹. Interestingly, the p.W322* mutation in our patients is also associated with the same *DGKE* haplotype (Supplementary Table 2). The second mutation p.P498R is a novel genetic variation that results in an amino acid substitution in exon 11 of the *DGKE* gene; a region that encodes the kinase accessory domain (Figure 2). p.P498R was not found in 140 normal control chromosomes and has not been reported previously in the available *DGKE* mutation databases. We lack assays to test the functionality of the *DGKE* mutations and have no biopsy material from the patients to test DGK- ϵ expression. However, a very strong argument supporting that p.P498R is a *DGKE*

deleterious mutations is that the patients carrying this mutation present it together with the deleterious p.W322* mutation (patients are compound heterozygotes), which is in agreement with the recessive model of inheritance described for pathogenic *DGKE* mutations. It would be extremely unlikely that this pairing of mutations would have occurred by chance if such infrequent genetic variants were not pathogenic. Furthermore, we have used bioinformatics prediction tools that discriminate neutral polymorphisms from amino acid substitutions of likely functional importance to support that the identified *DGKE* changes represent true disease mutations (see Materials and Methods). These *in silico* analyses indicate that p.P498R is a damaging mutation (Table 4).

Genetic analysis in these patients revealed that both patients are also heterozygotes for a mutation in *THBD* (c.1456G>T; p.D486Y) previously found associated with aHUS and demonstrated to be pathogenic¹⁶ (Figure 1). *CFH* and *MCP* genotyping showed that HUS39 and HUS40 are heterozygotes for the *MCP* and *CFH* aHUS risk haplotypes, respectively. The search for anti FH autoantibodies was negative and the complement plasma levels were normal, although C3 levels in these individuals, particularly HUS40, were in the lower part of the normal range (Table 3).

Patients with concurrent mutations in DGKE and C3.

HUS272 is a 4y-old female from a German-Spanish family who presented with aHUS at 8mo of age, coincident with an upper respiratory tract infection. She had periorbital edema, low plasma total protein levels, hematuria and nephrotic proteinuria (Table 2). After 48h she developed generalized edema, hypertension, thrombocytopenia and schistocytes were observed at the peripheral blood smear. A biopsy supported the diagnosis of aHUS. She evolved favorably with a progressive decrease of proteinuria levels. Eight months later, coincident with a vaccination, she suffered an episode of oliguria and edema, associated with increased proteinuria, which resolved raising the Enalapril dosis. However, three months later, after an acute upper tract infection, she

had an aHUS recurrence and her clinical situation deteriorated. C3 was slightly below normal range. She initiated biweekly plasma infusions, which led to stabilization of the clinical symptoms and near normalization of all blood parameters (Figure 3); however proteinuria and gross hematuria persisted. One year later, C3 levels dropped to 0.77g/l, the edema returned and her clinical situation worsened again. It was decided to switch her from the biweekly plasma infusions to Eculizumab treatment and thereafter her clinical situation improved significantly. However, a urine sample revealed ongoing proteinuria. She is currently treated biweekly with Eculizumab and the clinical situation had much improved. Previously, she always had peripheral edema when she had infections, under Eculizumab treatment, however, she remained without obvious edema (Table 2; Supplementary Data).

Genetic analysis showed that HUS272 is a compound heterozygote for a non-sense mutation (c.1452del; p.G484Gfs*10) in exon 11 of *DGKE* that truncates the last 69 amino acids of the protein (most likely deleterious) and a missense mutation (c.744G>C; p.Q248H) in exon 4 of the *DGKE* gene, encoding the kinase catalytic domain of DGK- ϵ (Figures 1 and 2 and Table 1). p.G484Gfs*10 and p.Q248H are novel mutations that were not found in 140 normal control chromosomes and have not been reported previously in the available *DGKE* mutation databases. Similarly to the case of the p.P498R mutation found in HUS40 and HUS39, the concurrence of p.G484Gfs*10 and p.Q248H in HUS272 and the results of their analysis *in silico* strongly support that these *DGKE* mutations are pathogenic (Table 4).

Critically, the analysis of all known aHUS genetic risk factors showed that HUS272 carries in addition to the *DGKE* mutations a novel mutation in the *C3* gene (c.784G>T; p.G262W) (Figure 1) that *in silico* analysis also clearly identified as a damaging mutation (Table 4). p.G262W was not found in 140 normal control chromosomes and is not included in genetic variation databases. Interestingly, this patient carries the *C3* mutation in combination with a *MCP* risk haplotype in homozygosity (Table 3), which is characteristic of aHUS patients carrying gain-of-function mutations in *C3* and *CFB*^{13, 32}.

Complement plasma levels were normal, although C3 levels in this patient were always below or in the lower part of the normal range (Table 3). Notably, her mother who is also a carrier of the p.G262W C3 mutation also presents decreased plasma C3 levels (Figure 3A).

DISCUSSION

Previous studies have identified two groups of patients with mutations in the *DGKE* gene. Ozaltin et al.²⁰ reported 9 patients from three consanguineous pedigrees presenting with MPGN with histological signs of both glomerular microangiopathy and endothelial distress at ages ranging from 0.8 to 17y-old. No complement data were reported for these patients²⁰. A second study by Lemaire et al.¹⁹, reported 13 patients from 9 unrelated pedigrees also carrying mutations in *DGKE*. In contrast, all these patients presented within the first year of life with aHUS. Notably, these patients belong to a group of pediatric-onset aHUS that was selected to include only patients in whom mutation in known aHUS-associated genes or anti FH auto-antibodies have not been identified¹⁹. Here we have analyzed the *DGKE* gene in our aHUS cohort and found that 5% (4/83) of our early-onset patients carry *DGKE* mutations, including both carriers and non-carriers of mutations in other aHUS-associated genes.

Disease presentation and evolution in our four patients was comparable to that of patients carrying *DGKE* mutations described by Lemaire et al.¹⁹ These patients met the clinical criteria for aHUS at presentation, with disease recurrences within the early childhood. Later on, one of them clearly progressed to the chronic glomerulopathy with hematuria, proteinuria, hypertension and renal failure, which is distinctive of *DGKE* mutation carriers from other aHUS patients (Table 2)

Interestingly, we found that three of our patients also carry mutations in other known aHUS-associated genes. Clinical course and severity of the disease in these patients was different from those of the patient with isolated *DGKE* mutations. HUS39 and HUS40, who also carry a pathogenic heterozygous mutation in *THBD*, had various aHUS recurrences shortly after the disease onset that responded well to daily plasma infusions. Notably, the course of the disease was more benign in the affected brother (HUS39) who was intensively treated with plasma immediately after the onset of the disease (Table 2). These data point to a potential beneficial effect of plasma infusions in our patients and argue previous remarks, based on data from patients carrying

exclusively loss-of-function *DGKE* mutations, not supporting the use of plasma in affected carriers of *DGKE* mutations¹⁹. Notably, it has been reported that most (88%) aHUS patients associated with *THBD* mutations responded well to plasma therapy³³. Therefore, we like to suggest that the association of a *THBD* mutation with the *DGKE* mutations in HUS39 and HUS40 results in a potentially more severe phenotype due to an increased frequency of aHUS recurrences caused by the *THBD* mutation. Consistently with other aHUS patients carrying *THBD* mutations, our patients responded well to plasma therapy.

HUS272, who in addition to the *DGKE* mutations also carries a likely pathogenic heterozygous mutation in *C3* and the *MCP* risk haplotype in homozygosity, also presented several aHUS recurrences, shortly after onset. Biweekly plasma infusions were effective in normalizing blood parameters, and subsequent Eculizumab treatment resolved the infection-associated edemas that were typical in this patient (Figure 3). In comparison with the rest of patients in this case series with *DGKE* mutations, the association of a *C3* gene mutation in this particular patient possibly contributed to a more severe disease with chronic activation of thrombotic microangiopathy despite plasma treatment and, more importantly, to a positive response to complement C5 blockage with Eculizumab, which conducted to remission.

Finally, HUS299, carrying exclusively *DGKE* mutations, recovered renal function without plasma infusions or Eculizumab treatment and has remained stable without recurrences since the aHUS onset, three years ago (Table 2).

These findings support a potential role of mutations in complement genes in patients carrying *DGKE* loss-of-function mutations. The novelty of our approach has been searching for *DGKE* mutations in aHUS patients with and without mutations in known aHUS associated complement genes. It is remarkable that after screening 83 aHUS patients with a very early onset (<2y), without excluding those with previously identified mutations in known aHUS-associated genes (21 patients), we found three patients carrying recessive *DGKE* mutations who also carry mutations in other known aHUS-

associated genes and just one patient with isolated *DGKE* mutations. These data, and the evident correlation of disease recurrences with infection in our patients (Supplementary Data), suggest that the onset and severity of the chronic renal pathology associated with *DGKE* mutations may be influenced by additional complement-related aHUS risk factors. If these data are replicated in other aHUS cohorts and a role for complement dysregulation is finally established in *DGKE*-related aHUS, the suggestion that current treatment based on plasma therapy and complement inhibition are not beneficial in individuals with *DGKE* mutations should, perhaps, be reconsidered; at least for patients in whom there is coexistence of *DGKE* and complement gene mutations. Preventing complement-related thrombotic microangiopathy episodes may result in a more benign course of the renal disease in carriers of *DGKE* mutations.

In conclusion, we found that 5% of the patients in our aHUS cohort who had a very early onset of the disease (<2y) carry recessive mutations in *DGKE*. Although this is a small percentage compared to the 27% reported for the French cohort, it is still a significant number. Our patients carry a total of 5 different mutations in the *DGKE* gene. Four of them are novel mutations and one (p.W322*) seems to be a relatively prevalent mutation of European origin. The disease presentation and evolution in our patients was comparable to that of patients carrying *DGKE* mutations described by Lemaire and coworkers in the French aHUS cohort¹⁹. However, in contrast with that previous study, we found that three of our patients carry additional mutations in the known aHUS candidate genes *C3* and *THBD*. Although further analysis in other aHUS cohorts are needed to replicate our findings, these data suggest that complement-mediated aHUS episodes have a role modulating the onset and severity of renal disease in carriers of *DGKE* mutations. Finally, this work further illustrates that a comprehensive understanding of the genetic component predisposing to the pathology is critical to guide appropriate diagnostics and effective treatment in aHUS.

ACKNOWLEDGEMENTS

We are grateful to the patients and their relatives for their participation in this study. We also thank Dr. Gema Ariceta for comments and suggestions during the preparation of this manuscript. We are also indebted with Drs J. Perez and L. Olavarrieta from Secugen SL for invaluable help in the design for the *DGKE* sequencing strategy. Work in this report has been funded by the Spanish “Ministerio de Economía y Competitividad” (SAF2011-26583), the Fundación Renal Iñigo Alvarez de Toledo and the Seventh Framework Programme European Union Project EURenOmics (305608) to SRdeC; the Spanish “Ministerio de Economía y Competitividad”: (PI1200597) to PS-C; and the Spanish “Ministerio de Economía y Competitividad” (PS09/00122; SAF2012-38636) to MLT. In addition, this work has been supported by a grant from the Autonomous Region of Madrid (S2010/BMD-2316) to SRdeC, MLT and PS-C.

DISCLOSURES

SRdeC, BH, MA and LL have received honoraria from Alexion Pharmaceuticals for giving lectures and participating in advisory boards. None of these activities has had any influence on the results or interpretation in this article. Other authors declare no conflicts of interest.

REFERENCES

1. Noris M, Remuzzi G. Hemolytic uremic syndrome. *J Am Soc Nephrol.* 2005;16:1035-1050.
2. Constantinescu AR, Bitzan M, Weiss LS, et al. Non-enteropathic hemolytic uremic syndrome: causes and short-term course. *Am J Kidney Dis.* 2004;43:976-982.
3. Caprioli J, Bettinaglio P, Zipfel PF, et al. The molecular basis of familial hemolytic uremic syndrome: mutation analysis of factor H gene reveals a hot spot in short consensus repeat 20. *J Am Soc Nephrol.* 2001;12:297-307.
4. Caprioli J, Castelletti F, Bucchioni S, et al. Complement factor H mutations and gene polymorphisms in haemolytic uraemic syndrome: the C-257T, the A2089G and the G2881T polymorphisms are strongly associated with the disease. *Hum Mol Genet.* 2003;12:3385-3395.
5. Perez-Caballero D, Gonzalez-Rubio C, Gallardo ME, et al. Clustering of missense mutations in the C-terminal region of factor H in atypical hemolytic uremic syndrome. *Am J Hum Genet.* 2001;68:478-484.
6. Richards A, Buddles MR, Donne RL, et al. Factor H mutations in hemolytic uremic syndrome cluster in exons 18-20, a domain important for host cell recognition. *Am J Hum Genet.* 2001;68:485-490.
7. Warwicker P, Goodship TH, Donne RL, et al. Genetic studies into inherited and sporadic hemolytic uremic syndrome. *Kidney Int.* 1998;53:836-844.
8. Esparza-Gordillo J, Goicoechea de Jorge E, Buil A, et al. Predisposition to atypical hemolytic uremic syndrome involves the concurrence of different susceptibility alleles in the regulators of complement activation gene cluster in 1q32. *Hum Mol Genet.* 2005;14:703-712.
9. Noris M, Brioschi S, Caprioli J, et al. Familial haemolytic uraemic syndrome and an MCP mutation. *Lancet.* 2003;362:1542-1547.
10. Richards A, Kemp EJ, Liszewski MK, et al. Mutations in human complement regulator, membrane cofactor protein (CD46), predispose to development of familial hemolytic uremic syndrome. *Proc Natl Acad Sci U S A.* 2003;100:12966-12971.
11. Fremeaux-Bacchi V, Dragon-Durey MA, Blouin J, et al. Complement factor I: a susceptibility gene for atypical haemolytic uraemic syndrome. *J Med Genet.* 2004;41:e84.

12. Kavanagh D, Kemp EJ, Mayland E, et al. Mutations in complement factor I predispose to development of atypical hemolytic uremic syndrome. *J Am Soc Nephrol.* 2005;16:2150-2155.
13. Goicoechea de Jorge E, Harris CL, Esparza-Gordillo J, et al. Gain-of-function mutations in complement factor B are associated with atypical hemolytic uremic syndrome. *Proc Natl Acad Sci U S A.* 2007;104:240-245.
14. Fremeaux-Bacchi V, Miller EC, Liszewski MK, et al. Mutations in complement C3 predispose to development of atypical hemolytic uremic syndrome. *Blood.* 2008;112:4948-4952.
15. Dragon-Durey MA, Loirat C, Cloarec S, et al. Anti-Factor H autoantibodies associated with atypical hemolytic uremic syndrome. *J Am Soc Nephrol.* 2005;16:555-563.
16. Delvaeye M, Noris M, De Vriese A, et al. Thrombomodulin mutations in atypical hemolytic-uremic syndrome. *N Engl J Med.* 2009;361:345-357.
17. de Cordoba SR, de Jorge EG. Translational mini-review series on complement factor H: genetics and disease associations of human complement factor H. *Clin Exp Immunol.* 2008;151:1-13.
18. Legendre CM, Licht C, Muus P, et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. *N Engl J Med.* 2013;368:2169-2181.
19. Lemaire M, Fremeaux-Bacchi V, Schaefer F, et al. Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome. *Nat Genet.* 2013;45:531-536.
20. Ozaltin F, Li B, Rauhauser A, et al. DGKE variants cause a glomerular microangiopathy that mimics membranoproliferative GN. *J Am Soc Nephrol.* 2013;24:377-384.
21. Nozal P, Garrido S, Alba-Dominguez M, et al. An ELISA assay with two monoclonal antibodies allows the estimation of free factor H and identifies patients with acquired deficiency of this complement regulator. *Mol Immunol.* 2013;58:194-200.
22. Gonzalez-Rubio C, Ferreira-Cerdan A, Ponce IM, Arpa J, Fontan G, Lopez-Trascasa M. Complement factor I deficiency associated with recurrent meningitis coinciding with menstruation. *Arch Neurol.* 2001;58:1923-1928.
23. Abarrategui-Garrido C, Martinez-Barricarte R, Lopez-Trascasa M, de Cordoba SR, Sanchez-Corral P. Characterization of complement factor H-related (CFHR) proteins in plasma reveals novel genetic variations of CFHR1 associated with atypical hemolytic uremic syndrome. *Blood.* 2009;114:4261-4271.

24. Lopez-Trascasa M, Marin MA, Fontan G. C3 nephritic factor determination. A comparison between two methods. *J Immunol Methods*. 1987;98:77-82.
25. Sanchez-Corral P, Gonzalez-Rubio C, Rodriguez de Cordoba S, Lopez-Trascasa M. Functional analysis in serum from atypical Hemolytic Uremic Syndrome patients reveals impaired protection of host cells associated with mutations in factor H. *Mol Immunol*. 2004;41:81-84.
26. Martinez-Barricarte R, Heurich M, Valdes-Canedo F, et al. Human C3 mutation reveals a mechanism of dense deposit disease pathogenesis and provides insights into complement activation and regulation. *J Clin Invest*. 2010;120:3702-3712.
27. Tortajada A, Yebenes H, Abarategui-Garrido C, et al. C3 glomerulopathy-associated CFHR1 mutation alters FHR oligomerization and complement regulation. *J Clin Invest*. 2013;123:2434-2446.
28. Kumar P, Henikoff S, Ng PC. Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. *Nat Protoc*. 2009;4:1073-1081.
29. Adzhubei IA, Schmidt S, Peshkin L, et al. A method and server for predicting damaging missense mutations. *Nat Methods*. 2010;7:248-249.
30. Schwarz JM, Rodelsperger C, Schuelke M, Seelow D. MutationTaster evaluates disease-causing potential of sequence alterations. *Nat Methods*. 2010;7:575-576.
31. Tavtigian SV, Deffenbaugh AM, Yin L, et al. Comprehensive statistical study of 452 BRCA1 missense substitutions with classification of eight recurrent substitutions as neutral. *J Med Genet*. 2006;43:295-305.
32. Roumenina LT, Frimat M, Miller EC, et al. A prevalent C3 mutation in aHUS patients causes a direct C3 convertase gain of function. *Blood*. 2012;119:4182-4191.
33. Noris M, Caprioli J, Bresin E, et al. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. *Clin J Am Soc Nephrol*. 2010;5:1844-1859.

FIGURE LEGENDS

Figure 1. Pedigrees of the aHUS patients carrying *DGKE* mutations.

For each pedigree the index cases are indicated with arrows and the chromatograms for the corresponding mutations are shown. Segregation of the mutations is indicated with colored symbols. ND, indicates that genetic analysis have not been performed yet.

Figure 2. Location of the *DGKE* mutations found in Spanish aHUS patients.

A diagram of the DGK- ϵ protein depicting the different protein domains (HD, hydrophobic domain; C1 domain; kinase catalytic domain and kinase accessory domain) is shown. Arrows identify the position of the five mutations found in the screening of the early-onset Spanish aHUS patients.

Figure 3. Evolution of blood parameters in HUS272.

The evolution of the C3 (A), platelets (B) and lactate dehydrogenase (LDH) (C) serum levels in patient HUS272 from the disease onset are shown. Arrows indicate the start of the plasma therapy (FFP, fresh frozen plasma) and of the Eculizumab (Ecu) treatment, respectively. C3 levels in the mother (Mo) and father (Fa) are also indicated.

Table 1. *DGKE* and complement gene mutations found in early onset aHUS patients

Patient ID	<i>DGKE</i>		Other mutations
HUS39	Exon 6; c.966G>A; p.W322*	Exon 11; c.1493C>G; p.P498R	<i>THBD</i> ; c.1456G>T; p.D486Y
HUS40	Exon 6; c.966G>A; p.W322*	Exon 11; c.1493C>G; p.P498R	<i>THBD</i> ; c.1456G>T; p.D486Y
HUS272	Exon 4; c.744G>C; p.Q248H	Exon 11; c.1452del; p.G484Gfs*10	<i>C3</i> ; c.784G>T; p.G262W
HUS299	Exon 12; c.1608_1609del; p.H536Qfs*16	Exon 12; c.1608_1609del;p.H536Qfs*16	None

Table 2. Clinical characteristics of the aHUS patients carrying *DGKE* mutations.

Patient	Gender	Age (years)	Age at onset (months)	Proteinuria onset Alb(g)/Cr(g)	Thrombocytopenia onset	LDH(U/L) / Schisto.	sCr onset (mg/dL)	Dialysis onset	Histology	aHUS recurrences	Plasma infusions	Ecu therapy	Last sCr (mg/dL)	Last Hematuria	Last Proteinuria Alb(g)/Cr(g)
HUS299	M	4	13	8	Yes	2138/Yes	7.7	Yes	ND	No	No	No	0.4	None	0.05
HUS39	M	11	3	>3	Yes	2727/Yes	2.8	Yes	ND	Yes (1)	Yes	No	0.8	None	None
HUS40	F	17	7	>3	Yes	4560/Yes	4	Yes	TMA	Yes (3)	Yes	No	1.5	None	0.3
HUS272	F	4	8	12	Yes	1032/Yes	0.4	No	TMA	Yes (>3)	Yes	Yes	0.3	+++	4.4

Abbreviations: Alb, albumin; Cr, creatinine; LDH, lactate dehydrogenase; Schisto, schistocytes; sCr, serum creatinine; Ecu, eculizumab; M, male; F, female; TMA, thrombotic microangiopathy.

Table 3. Complement profiles in aHUS patients carrying mutations in *DGKE*.



Patient	Polymorphisms			Complement assessment *					
	<i>CFHR3-CFHR1</i> Deletion	<i>CFH</i> Risk haplotype	<i>MCP</i> Risk haplotype	FH 12-56mg/dL	C3 90-200mg/dL	C4 16-38mg/dL	FI 71-115%	MCP (PBLs)	Anti-fH
HUS299	Het	Het	No	29.7	163	24.2	80	Normal	Neg
HUS39	No	No	Het	31	124	27.4	73	ND	Neg
HUS40	No	Het	No	35.3	87.8	21.6	83	ND	Neg
HUS272	Het	No	Hom	15	86.9	23.6	>100	Normal	Neg

(*) Complement studies were performed at different times after onset as follows: HUS39, 7 months; HUS40, 6 years; HUS272, 10 weeks; and HUS299, 3 weeks.


Abbreviations: Het, heterozygote; Hom, homozygote; *CFH*, gene encoding factor H; *MCP*, gene encoding membrane cofactor protein; FH, factor H; C3, complement C3; C4, complement C4; FI, factor I; MCP, Membrane cofactor protein; PBLs, peripheral blood lymphocytes; Anti-FH, auto antibodies against factor H; Neg, negative.

Table 4. *In silico* analyses of missense mutations.


Mutation	Polyphen (0-1)	SIFT (1-0)	Align-GVGD (C0 – C65)	MutationTaster (0-1)
<i>DGKE</i> ; c.744G>C; p.Q248H	0.999 Damaging	0 Damaging	C15 Low risk	0.999 Disease causing
<i>DGKE</i> ; c.1493C>G; p.P498R	1 Damaging	0.05 Damaging	C65 High risk	0.999 Disease causing
<i>C3</i> ; c.784G>T; p.G262W	1 Damaging	0 Damaging	C65 High risk	0.999 Disease causing





▲ *DGKE c.966G>A*; p.W322*




● *DGKE c.1493C>G*; p.P498R




■ *THBD c.1456G>T*; p.D486Y





▲ *DGKE c.744G>C*; p.Q248H




● *DGKE c.1452del*; p.G484Gfs*10






■ *C3 c.784G>T*; p.G262W



● *DGKE c.1608_1609del*; p.H536Qfs*16



A**B****C**

Supplementary Data

HUS299

HUS299 is a 4y-old male from Marroco who presented with aHUS at 13m-old, coincident with a 7d-long vomiting and diarrhea episode. The analytic parameters at admission were: hemoglobin 7.7g/dL; hematocrit 21.8%; platelets 202,000/ μ L; LDH 2138U/L; haptoglobin <0.15mg/dL; creatinine 7.7mg/dL and urea 245mg/dL. Schistocytes were present in the peripheral blood smear. He was oliguric and required peritoneal dialysis during 22 days. During that period, anemia progressed and thrombocytopenia dropped to 17,000 platelets/ μ L, requiring transfusions. Severe hypertension was controlled with Enalapril and Amlodipine. He evolved well and recovered renal function, with only a residual proteinuria of 0.28g/L, discrete anemia (Hg 10g/dL) and normal platelets and serum LDH. Two years after remission, the patient remains asymptomatic and without recurrences. By August 2013 he had normal blood pressure and proteinuria further decreased, remaining only a residual microalbuminuria (MAU/Cr 53.4mg/g). A renal ultrasound at that time was normal.

HUS40 and HUS39

HUS40 and HUS39 are siblings from an Argentinean family of European ancestry. HUS40 is a 17y-old female who at 7mo of age presented an episode of thrombotic microangiopathy. Since STEC-HUS is endemic in that country, it was taken as a typical case evolving satisfactorily. Five months later, however, she had a recurrence that required hemodialysis and continuous ambulatory peritoneal dialysis for few months. aHUS was then suspected and a renal biopsy performed at that time revealed glomerular thrombotic microangiopathy. She evolved satisfactorily from this recurrence, partially recovering renal function without dialysis requirement. A third recurrence occurred at 2y old, following an upper respiratory tract infection. She responded well to a protocol of daily plasma infusions that were spaced progressively and suspended one year later. During the last 14 years she had not suffered any more recurrences. At

the last control, on December 2013, she was clinically well, with normal blood parameters, serum creatinine of 1.5mg/dL and Ccr of 41mL/min/1.73m². Her hypertension and residual proteinuria is currently treated with Enalapril and Losartan. HUS39 is a 11y-old male, who in December 2002 presented with aHUS at the early age of 3mo-old. He had severe thrombocytopenia and petechial rash and was anuric, requiring acute peritoneal dialysis. Based on the experience with his sister (HUS40), he was immediately treated with daily plasma infusions. After 10 days, his renal function improved and he was discharged maintaining the daily plasma infusions for two months (10mL/kg/day). Interestingly, when plasma infusions were spaced biweekly he had an aHUS recurrence that responded well when plasma infusions were returned to daily basis. Based on his clinical improvement, plasma infusions were again spaced progressively and finally suspended on December 2007. At the last control, on December 2013, he was clinically well, with normal blood parameters, serum creatinine of 0.8mg/dL and Ccr of 57mL/min/1.73m². Like his sister, he is under Enalapril and Losartan.

HUS272

HUS272 is a 4y-old female from a German-Spanish family who in October 2010, at 8mo of age, presented with aHUS coincident with an upper respiratory tract infection. She had periorbital edema, low plasma total protein levels (35g/dL), sCr 0.6mg/dL, Hb 13.4g/dL, 362,000 platelets/ μ L, hematuria and nephrotic proteinuria (597mg/m²/h). After 48h she developed generalized edema, hypertension and thrombocytopenia (129,000 platelets/ μ L) and 6-16% schistocytes were observed at the peripheral blood smear. A biopsy performed on January 2011 revealed the presence of glomerular thrombotic microangiopathy, supporting the diagnosis of aHUS. ADAMST-13 activity was 98.8%. She evolved favorably under Furosemide and Enalapril treatment with a progressive decrease of proteinuria levels. In June 2011, coincident with a vaccination

she suffered an episode of oliguria and edema, associated with increased proteinuria, which resolved raising the Enalapril dosis.

In November 2011, again after an acute upper tract infection, she had an aHUS recurrence and her clinical situation deteriorated. Her blood parameters at that time were: total plasma protein 52g/L, platelets 94,000/ μ L, Hemoglobin 11.2g/dL, LDH 635U/L, uric acid 7.7mg/dL. Her serum creatinine was 0.4mg/dL, but her cystatin C levels were slightly elevated (1.2mg/L). A kidney ultrasound revealed enlarged, hyperechoic kidneys. C3 was slightly bellow normal range. She initiated biweekly plasma infusions, which after four months led to stabilization of the clinical symptoms and near normalization of all blood parameters (LDH 346U/L, Hb 11.7g/dL, Platelets 350,000/ μ L, C3 1.06g/L); however proteinuria and gross hematuria persisted.

In November 2012, C3 levels dropped to 0.77g/L, the edema returned and her clinical situation worsened again. It was decided to switch her from the biweekly plasma infusions to Eculizumab treatment and thereafter her clinical situation improved significantly. Her plasma total protein increased to 64g/L, her serum albumin to 42.5 g/L, serum creatinine was 0.18mg/dL, serum cystatin C 0.56mg/dL, LDH 366U/L and C3 0.99g/L. Platelets and LDH were normal (no alteration of these parameters were ever seen again after November 2011, neither under plasma infusions nor Eculizumab treatment). However, a urine sample in May 2013 revealed ongoing proteinuria. She is currently treated biweekly with Eculizumab and the clinical situation had much improved. Previously, she always have had peripheral edema when she had infections, under Eculizumab treatment, however, she remained without obvious edema. Her current values are: serum creatinine 0.3mg/dL, LDH 315U/L, total protein 48g/L, albumin 23g/L, C3 1.32 g/L, 465,000 platelets/ μ L, Hb 10.9g/dL and Alb(g)/Cr(g) of 4.4.

Supplementary Table 1. PCR primers for *DGKE* exon amplification and sequencing.

Primer Name	Sequence 5' to 3'
DGKE-Exon 2F	CAGCTTGCCCCTGTATGTTG
DGKE-Exon 2R	TCAAATGAGTTTAGGTCATCAGC
DGKE-Exon 3F	TTCACTGTGCAGATAGTGCAT
DGKE-Exon 3R	TAAATCATTGAGATGCAGGC
DGKE-Exon 4F	AATTTCTGAGGTTCCCTTCC
DGKE-Exon 4R	CTGGGCTGTTTATGCTTTTC
DGKE-Exon 5F	ATAAAGAGTCTGGCAGGGTG
DGKE-Exon 5R	CAGGAGTTTGACAGCAGC
DGKE-Exon 6F	GCACAAGCTTTAGCAAACA
DGKE-Exon 6R	GAGCATGCAAATTTAGGGAT
DGKE-Exon 7F	GCATGCTCATATACGTGTGG
DGKE-Exon 7R	ACCTAGTGCAGGCTTCTGAG
DGKE-Exon 8cF	TGGACAGTATAAAATAGCCATGTG
DGKE-Exon 8cR	GATCTAATTTGACAACCCTACACA
DGKE-Exon 9F	AAGGAGAATGTGTGCTTCAA
DGKE-Exon 9R	TGTTGAGTCAGGCACTGTATT
DGKE-Exon 10F	TGAGAGGTAGGGAGCATCTT
DGKE-Exon 10R	TTGGGACAAATTAGCCTGTT
DGKE-Exon 11F	AAGTTGATGGTCCAACCTGTGTT
DGKE-Exon 11R	CACAATCCCTTAACCCTTATGC
DGKE-Exon 12F	TGCATAAGGGTTAAGGGATTG
DGKE-Exon 12R	TAACTGAAGGCTGGCTGGTT

Supplementary Table 2. DGKE haplotype associated with the W322* mutation.

	rs2235092	rs7225724	rs6503772		rs4794670	rs11651692	rs7209070
European Haplotype (ref.19)	G	G	A	W322* Mutation	A	G	C
HUS 39	G	G	A		A	G	C
	A	G	A		T	A	C
HUS 40	G	G	A		A	G	C
	A	G	A		T	A	C